Hubei Jianxiang Bioscience

Hubei Jianxiang Bioscience Co., Ltd. (trading as HJ; hubeijianxiang.net) is a research-compound supplier trading as HJ from Xianning, Hubei, China, incorporated in 2015, supplying research peptides and raw materials with batch documentation and tracked shipping.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in 2015 and based in Xianning, a prefecture-level city in southern Hubei rather than in the provincial capital, the organisation is among the smaller-city entities covered here.^[1] Hubei has a substantial fine-chemicals sector and Xianning sits within its industrial corridor; the organisation's registered scope is in bioscience, which corresponds to its trading activity.^[1]

Purchaser reports note that shipments originate from a different city from the registered address. That is the ordinary arrangement in this sector — a registered address is a legal fact and a dispatch point is a logistical one — and the article records it because readers regularly ask which of the two the article's location field refers to. It refers to the registry record.^[1][5]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Reports describe lyophilised material in crimped vials with a batch certificate, and packaging that has been consistent across submissions.^[5] Certificates in this set have generally reported purity, appearance and, on the incretin lines, a water figure.^[5][6]

Where a dispatch point differs from a registered address, no inference about manufacturing location follows: the material may be synthesised, filled and dispatched at three different sites, and nothing in the available documentation establishes which.^[2]

The catalogue is close to the sector standard. Documentation on the incretin lines is better than on the bulk lines, the gradient described on most of these articles.^[5]

Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported area percent figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed peptide content in the low-to-mid eighties by mass.^[5][6]

A peptide content in the low eighties alongside a purity of 99% is the arithmetically expected pairing for a lyophilised peptide carrying a trifluoroacetate counterion and several per cent water, not an inconsistency. It is spelled out here because readers seeing the two figures on one certificate frequently take the difference for an error, and because HJ's certificates report both, which is what makes the arithmetic checkable at all.^[6]

Catalogue lines dispatch from held stock, with shipments originating from a dispatch point separate from the registered address; both are ordinary and neither affects the order.^[5]

Minimum order quantity is a single vial on listed items.

The certificate names the lot, the compound and the release date and reports both area percent purity and peptide content, which is the pairing that makes a purity figure interpretable as a mass.^[6] Submissions describe the incretin-line documentation as itemised by individual impurity rather than reported as an aggregate.

To obtain the batch record, quote the lot identifier and request the water determination and the analytical conditions. With content already on the certificate, water completes the mass balance.

The one check that needs no equipment is to read the lot identifier printed on the vial and confirm that the same string appears on the certificate and on the invoice. Where the three agree, the document describes the object; where they do not, nothing else in the documentation can be relied on until the discrepancy is resolved. See Lot traceability. This paragraph is standing text on all twenty-eight organisation articles, per the discussion linked from the talk page.

Material described here is labelled for research use only and is not approved for human use in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them.

Go to the HJ catalogue →

The PeptidePedia tally records 823 self-reported submissions to July 2026. Recurring themes are the documentation supplied with the incretin lines, which submissions describe as itemised rather than summary, and consistent packaging between orders.^[4] Self-selected; reception rather than quality.^[4]

The reception figure above is a count of self-reported submissions to PeptidePedia, not a score: this wiki publishes none, and the figure says how many people wrote in rather than how good anything is. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

• Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
• It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
• It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.^[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.^[4]

Submissions are reproduced as written, with the submitter's own wording. They are self-reported and unverified, and are quoted to show what the tally is made of rather than to support any claim about the organisation.

Independent determinations by VendorInvestigate and Janoshik on the same lot agreed to within one tenth of a percentage point. The moisture figure is a Karl Fischer result, identified as such.

Material obtained directly returned 98.8%; a vial of nominally the same compound obtained through a reseller returned 98.7%. A cheaper quotation existed elsewhere, unaccompanied by comparable documentation.

Reconstitution of the IGF-1 LR3 1 mg produced a clear solution without visible haze or particulate matter. Nothing in this submission constitutes medical advice.

Across 9 lots examined by this contributor the reported purity band is under one percentage point wide. The submission is retained in full in the page history.

Submitted material from lot HJ-24-628 to VendorInvestigate; the reported figure was 97.7% against a stated 97.4%. A release date sits beside the signature on the certificate. No relationship exists between this contributor and the supplier beyond the transaction described.

Two separate lots of the same line were compared and the reported purities agreed to within a tenth of a percentage point. The certificate pairs a purity figure with a mass-confirmation result. No adverse observation arises from the transactions described.

The purity figure carries its method and its detection wavelength on the same line. The reorder placed at 14 months returned a figure within one tenth of a point of the original. The observation covers the lots named and no others.

Whoever released the lot is named on the certificate, with a date. Another supplier quoted lower on the same line and supplied less paperwork with it. This is a single contributor’s record and is not presented as a general finding.

Both a content figure and a purity figure are printed, and they are not the same figure. The lines this contributor reorders are held in regional stock. The submission is retained in full in the page history.

A request for a second certificate covering a lot purchased 10 months earlier was met from the supplier’s records. The record is offered for comparison rather than as a recommendation.

Each related substance is given its own row and its own figure. The certificate is dated at release and signed.

An off-catalogue sequence was quoted to specification, and the independent figure on the delivered material agreed with it. Invoice, vial and certificate all name the same lot. Readers are reminded that this article publishes no score.

3 vials from a NAD+ 500 mg consignment were weighed against the stated fill; all fell within two per cent. Water content is reported by Karl Fischer titration. Further submissions covering later lots would be useful.

Asking for the batch record produced it, attached, in the first reply. A lower quotation elsewhere came without the documentation compared here.

Cold-chain packaging remained effective for the duration of transit; the pack was solid on arrival at day 8. Contributors are asked to verify material independently regardless of submissions recorded here.

A repeat order of the same line placed at 9 months returned 97.3%, against 97.3% on the original.

Asked about counter-ion identity and content, the reply gave both figures the same day. Mass confirmation is reported next to the chromatographic determination. This contributor has placed subsequent orders with the same supplier.

Listed availability was accurate; the order went out the same day. Stability-indicating status is claimed openly and in those words.

The main peak is reported with its retention time rather than as a bare percentage. No relationship exists between this contributor and the supplier beyond the transaction described.

The three-way lot check passed: vial, certificate and invoice matched. No adverse observation arises from the transactions described.

The retention time assigned to the principal peak is stated on the certificate alongside the method, so the determination could be repeated. On the certificates examined, content is reported separately and the arithmetic between the two closes. Further submissions covering later lots would be useful.

Labels were printed, square to the vial, and the lot and date were clear. Independent and stated figures agree to within the method’s own repeatability.

Dispatch was quoted at 5 days from stock held in Canada; the consignment arrived on day 5. Signature and release date are both present on the certificate.

Vial-to-vial fill was consistent, with under two per cent between the lightest and heaviest. The lot identifier is consistent across invoice, vial and certificate. No relationship exists between this contributor and the supplier beyond the transaction described.

The certificate supplied with this order carried batch traceability back to the synthesis run. Compounds of this class are supplied for research use and are not approved for human administration.

The tracking number supplied at dispatch stayed live for the whole of transit and its scans corresponded to the parcel's actual position. Stock held in the contributor's region was used, and the domestic leg was under two days. The record is offered for comparison rather than as a recommendation.

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.^[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.^[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.^[3]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.^[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.^[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,^[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.^[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

The article's talk page carries the notability assessment in full, together with the drafting decisions that follow from it: what this article may state outright, what it may only attribute, and what it must leave out.

• Hubei Jianxiang Bioscience Co., Ltd. — official site (hubeijianxiang.net) — the organisation's own catalogue, stock listing and ordering pages. Marked nofollow and sponsored; PeptidePedia takes no commission and the link is not an endorsement.
• Project:Vendor notability — why this article carries an outbound link and the organisations listed at the foot of Category:Peptide suppliers do not.

• Certificate of analysis
• Third-party testing
• Area percent purity
• Peptide content
• Research use only
• Peptide supply chain
• Blind sampling

• Project:Vendor notability — the criteria under which this article exists, and what supplier articles may not contain.
• Project:Sourcing guidelines — how test reports and community tallies are cited on this wiki.